NewAmsterdam Pharma Company's total assets for Q2 2025 were $815.11M, a decrease of -0.40% from the previous quarter. NAMS total liabilities were $36.62M for the fiscal quarter, a -10.80% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.